Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Oral Delivery (Focus Group – OrD)

Oral delivery of adalimumab with BIONDD® technology achieving bioavailability comparable to s.c. injection

Liv von Voss – Senior Scientist Nonclinical Development, Biograil ApS; Carmen Milian Guimera – Research Scientist, Biograil ApS; Anne Tungelund Larsen – Director Pharmaceutical Research, Biograil ApS; Nils Piwon – Chief Development Officer, Biograil ApS; Karsten Lindhardt – CEO & Founder, Biograil ApS; Nikolaj Skak – CTO & Founder, Biograil ApS

    Poster Presenter(s)

  • Nina Mertz

    Senior Scientist
    Biograil ApS
    Roskilde, Hovedstaden, Denmark

Introduction:

Monoclonal antibodies such as adalimumab, are highly effective therapeutics for a range of diseases, yet their administration remains limited to injections, posing challenges for patient comfort and adherence [1]. Oral delivery of biologics is hindered by enzymatic degradation and poor epithelial permeability in the gastrointestinal tract [1,2]. The BIONDD® technology is a novel oral drug delivery combination product, designed to deliver biologics directly into the gastric wall, bypassing traditional absorption barriers (Figure 1) [3]. In this study, we evaluated the BIONDD® for oral delivery of adalimumab in beagle dogs, with subcutaneous (s.c.) injection as reference.

Learning Objectives:

  • Describe the BIONDD® technology and its mechanism for gastric wall delivery of biologics.
  • Understand the PK performance of orally delivered adalimumab using BIONDD® compared to s.c. administration.
  • Recognize how gastric wall delivery can make biologic therapy more patient-friendly.